Adaptive Biotechnologies Bolsa (NASDAQ: ADPT)

Últimas noticias sobre Adaptive Biotechnologies (NASDAQ:ADPT) Bolsa

Adaptive Biotechnologies

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adeptus Health

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

Equities

Tech

ETFs

ARKG

ARKK

CDNA

PLTR

VCYT

Ark Invest sorprende con grandes movimientos en Palantir y Tempus AI. Descubre el impacto de estas decisiones clave.

Cathie Wood apuesta 12,2M$ en Tempus AI (TEM) mientras reduce exposición a Palantir (PLTR)

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

On Friday, Cathie Wood-led Ark Invest made significant trades, with a particular focus on the tech and hospitality sectors.
The most prominent trades of the day involved shares of Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), BWX Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>), Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>), and Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>). Meanwhile, Ark Invest sold off shares of Circle Internet Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NASDAQ">CRCL</a>), DoorDash Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NYSE">DASH</a>) and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)
The ABNB Trade: Ark Invest&#8217;s ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) fund purchased 162,255 shares of Airbnb, a move that signals confidence in the hospitality industry&#8217;s recovery. The value of this trade, based on the closing price of the day, is around $21.73 million.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/46041090/tesla-faces-safety-questions-from-regulators-ahead-of-robotaxi-launch-in-austin">Tesla Faces Safety Questions From Regulators Ahead Of Robotaxi Launch In Austin</a>
The AMD Trade: Ark Invest&#8217;s ARKK and ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) funds bought a total of 189,060 shares of Advanced Micro Devices Inc. This investment comes amidst growing interest in the tech sector. The value of this trade, calculated from the closing price of the day, is around $24.25 million.
The SHOP Trade: Ark Invest&#8217;s ARKF and ARKK funds acquired a total of 166,093 shares of Shopify. This purchase underscores Ark Invest&#8217;s belief in the continued growth of e-commerce platforms. The value of this trade, based on the closing price of the day, is around $17.67 million.
The CRCL Trade: Ark Invest&#8217;s ARKF, ARKK, and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) funds sold a total of 615,175 shares of Circle Internet Group Inc. This decision follows <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/45964983/cathie-woods-monday-shuffle-buys-nvidia-sells-meta-ark-also-dumps-hot-circle-stock">Ark Invest&#8217;s earlier move</a> to offload shares of the company. The value of this trade, calculated from the closing price of the day, is around $147.81 million.
Other Key Trades:
<ul class="wp-block-list">
<li>Ark Invest&#8217;s ARKK fund bought 136,706 shares of BWX Technologies Inc.</li>
<li>Ark Invest&#8217;s ARKK fund bought 92785 shares of Taiwan Semiconductor Manufacturing Co. Ltd.</li>
<li>Ark Invest&#8217;s ARKK fund bought 218,039 shares of Robinhood Markets Inc.</li>
<li>Ark Invest&#8217;s ARKK fund bought 23963 shares of Veracyte Inc.</li>
<li>Ark Invest&#8217;s ARKF and ARKW funds bought a total of 21287 shares of DoorDash Inc.</li>
<li>Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) fund sold 13154 shares of Adaptive Biotechnologies Corp.</li>
</ul>
Read Next:
<a href="https://www.benzinga.com/news/politics/25/06/46041118/iran-halts-nuclear-talks-with-us-no-negotiations-until-israeli-aggression-stops-says-foreign-minister">Iran Halts Nuclear Talks With US: No Negotiations &#8216;Until Israeli Aggression Stops,&#8217; Says Foreign Minister</a>
<ul class="wp-block-list">
<li>Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</li>
</ul>
Photo courtesy: ChrisStock82 / Shutterstock.com

ABNB

ARKF

ARKW

BWXT

CRCL

DASH

HOOD

SHOP

Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Adaptive Biotechnologies, revealing an average target of $11.2, a high estimate of $15.00, and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 28.0% from the previous average price target of $8.75.
<img src="https://www.benzinga.com/files/images/story/2025/1750251656_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Adaptive Biotechnologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adaptive Biotechnologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Adaptive Biotechnologies compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Adaptive Biotechnologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Adaptive Biotechnologies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adaptive Biotechnologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Adaptive Biotechnologies</h2>
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
<h3>Adaptive Biotechnologies's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Adaptive Biotechnologies showcased positive performance, achieving a revenue growth rate of 25.24% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Adaptive Biotechnologies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -56.92%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Adaptive Biotechnologies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -15.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -5.68%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Adaptive Biotechnologies's debt-to-equity ratio is below the industry average at 0.46, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Adaptive Biotechnologies: Insights From 5 Financial Analysts

Craig-Hallum analyst John Wilkin initiates coverage on Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Buy rating and announces Price Target of $15.

Price Target

Initiation

Craig-Hallum Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $15

On Friday, Cathie Wood-led Ark Invest made some significant trades. The most prominent among these were in Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), 10X Genomics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 3D Systems Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>), and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The TSLA Trade: Ark Invest sold 6,511 shares of Tesla from its ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) fund. This move comes in the wake of significant developments for the electric vehicle giant, including insider sales and CEO Elon Musk&#8217;s decision to quit his government role.
The TXG and NTLA Trades: Ark Invest bought shares of 10X Genomics Inc. and Intellia Therapeutics Inc. from both its ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds.
The firm purchased 46031 shares of TXG and 30357 shares of NTLA from the ARKG fund, and 296148 shares of TXG and 196156 shares of NTLA from the ARKK fund.
The DDD Trade: Ark Invest sold shares of 3D Systems Corp. from its ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) and ARKX funds. The firm sold 36868 shares from the ARKQ fund and 11503 shares from the ARKX fund.
The ADPT Trade: Ark Invest sold 164741 shares of Adaptive Biotechnologies Corp. from its ARKG fund.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45708311/president-trump-proposes-1-billion-for-private-sector-mars-exploration-report">President Trump Proposes $1 Billion For Private Sector Mars Exploration: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

ARKQ

NTLA

TSLA

Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ&#xAE;&nbsp;test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).

Adaptive Biotechnologies Says NGS-Based clonoSEQ Test For MRD Assessment To Be Included In 30 Presentations At ASCO And EHA 2025

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $11 to $13.

Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $13

5 analysts have expressed a variety of opinions on Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Adaptive Biotechnologies, presenting an average target of $10.2, a high estimate of $12.00, and a low estimate of $9.00. This current average has increased by 24.39% from the previous average price target of $8.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1746475217_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Adaptive Biotechnologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adaptive Biotechnologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Adaptive Biotechnologies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Adaptive Biotechnologies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adaptive Biotechnologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Adaptive Biotechnologies</h2>
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
<h3>Financial Insights: Adaptive Biotechnologies</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Adaptive Biotechnologies showcased positive performance, achieving a revenue growth rate of 25.24% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Adaptive Biotechnologies's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -56.92%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Adaptive Biotechnologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -15.19%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Adaptive Biotechnologies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.68%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.46.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Adaptive Biotechnologies: What You Need To Know

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Equal-Weight and raises the price target from $7 to $9.

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $9

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 300 points on Friday.
The Dow traded up 1.43% to 41,337.37 while the NASDAQ climbed 1.76% to 18,023.33. The S&amp;P 500 also rose, gaining, 1.61% to 5,694.47.
Check This Out: <a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a>
Leading and Lagging Sectors Communication services shares jumped by 2.7% on Friday.
In trading on Friday, consumer staples stocks rose by just 0.6%.
Top Headline
Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell around 4% on Friday after the company reported results for its fiscal second quarter.
The company posted quarterly revenue of $95.36 billion, beating analyst estimates of $94.53 billion. The Cupertino-based company reported second-quarter earnings of $1.65 per share, beating analyst estimates of $1.63 per share.
The company&#8217;s CEO Tim Cook said that the tech giant expects a $900 million cost impact in the June quarter due to tariffs.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares shot up 295% to $1.0002. The company recently reported successful safety study of a formulation of PL-14 allergy blocker in human nasal tissue model.</li>
<li>Shares of Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>)got a boost, surging 111% to $2.0808 on continued strength after the company on Thursday announced it entered into an agreement for the issuance of convertible notes through a facility of up to $20 million. Capital from the financing will be earmarked for purchasing Official Trump Tokens.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares were also up, gaining 36% to $10.02 after the company reported first-quarter financial results and beat its EPS and revenue estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) shares dropped 34% to $0.1289 after the company announced a $1.5 million public offering.</li>
<li>Shares of Cable One, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>) were down 42% to $152.23 after the company reported worse-than-expected first-quarter financial results. Additionally, Keybanc downgraded the stock from Overweight to Sector Weight.</li>
<li>Draganfly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) was down, falling 35% to $1.9050 after the company priced a $3.6 million underwritten public offering at $2.10 per unit</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $58.38 while gold traded up 0.4% at $3,234.20.
Silver traded down 1% to $32.150 on Friday, while copper rose 1.2% to $4.6825.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.67%, Spain's IBEX 35 Index gained 1.2% while London's FTSE 100 rose 1.17%. Germany's DAX 40 rose 2.62% and France's CAC 40 added 2.33% during the session.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei gaining 1.04%, Hong Kong's Hang Seng Index surging 1.74% and India's BSE Sensex rising 0.32%.
Economics
<ul>
<li>Nonfarm payrolls increased by 177,000 last month, slightly down from a downwardly revised 185,000 in March, according to data released Friday by the Bureau of Labor Statistics. The outcome surpassed both economist forecasts for a 130,000 gain and betting markets – tracked by CFTC-regulated platform Kalshi – which had priced in a 90,000 increase.</li>
<li>The unemployment rate remained unchanged at 4.2%, as expected.</li>
<li>New order for U.S. manufactured goods rose by 4.3% to $618.8 billion in March.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

AAPL

CABO

DPRO

FRGT

PAPL

PLRZ

Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock moved upwards by 228.7% to $0.83 during Friday's regular session. The company's market cap stands at $33.1 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 73.84% to $0.7. The company's market cap stands at $7.9 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares moved upwards by 47.32% to $1.27. The market value of their outstanding shares is at $23.4 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares increased by 33.41% to $9.82. The market value of their outstanding shares is at $1.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 31.79% to $2.98. The market value of their outstanding shares is at $174.4 million. As per the press release, Q1 earnings came out today. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares rose 25.22% to $0.42. The company's market cap stands at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock fell 35.0% to $43.75 during Friday's regular session. The company's market cap stands at $142.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares decreased by 22.95% to $4.21. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) stock decreased by 21.0% to $14.41. The company's market cap stands at $1.8 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 19.49% to $62.0. The market value of their outstanding shares is at $806.7 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares decreased by 15.28% to $6.1. The company's market cap stands at $3.2 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock declined by 15.19% to $0.23. The company's market cap stands at $10.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ARDX

BIVI

HCTI

NDRA

PDEX

RSLS

12 Health Care Stocks Moving In Friday's Intraday Session

Goldman Sachs analyst Salveen Richter maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Buy and raises the price target from $9 to $10.

Goldman Sachs Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $10

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday.
Shares of Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/TRUP/earnings">raised its FY25 sales guidance</a>.
Trupanion reported quarterly loss of 3 cents per share which beat the analyst consensus estimate of loss of 5 cents per share. The company reported quarterly sales of $341.98 million which beat the analyst consensus estimate of $337.82 million.
Trupanion shares jumped 18.2% to $43.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares surged 30% to $9.60 after the company reported first-quarter financial results and beat its EPS and revenue estimates.</li>
<li>NPK International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NASDAQ">NPKI</a>) gained 26.6% to $7.65 after the company reported better-than-expected first-quarter financial results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 23.1% to $4.42.</li>
<li>Highest Performances Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPH#NASDAQ">HPH</a>) gained 23.1% to $7.20.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 20.8% to $10.37.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) climbed 17.4% to $26.96.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose 17.4% to $127.43 after the company reported better-than-expected first-quarter results and raised its FY25 sales guidance</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) gained 15% to $460.50 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) gained 13.7% to $79.87 following strong quarterly sales.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) jumped 12.4% to $7.74.</li>
<li>Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) gained 11.3% to $44.33 following first-quarter results.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) gained 11.1% to $52.40 after the company reported better-than-expected first-quarter sales results and raised its FY25 sales guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 10.6% to $9.39.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) gained 6.4% to $142.68 following first-quarter results.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose 6.3% to $49.58.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a></li>
</ul>

ACHR

ASTS

CART

DUOL

DXCM

EXAS

IRTC

NPKI

PONY

TRUP

WOLF

Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday

WIIM

Adaptive Biotechnologies shares are trading higher after the company reported Q1 financial results and beat its EPS and revenue estimates.

Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q1 financial results.

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.31) by 35.48 percent. This is a 39.39 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $52.40 million which beat the analyst consensus estimate of $42.68 million by 22.77 percent. This is a 25.14 percent increase over sales of $41.87 million the same period last year.

Earnings Beats

Adaptive Biotechnologies Q1 EPS $(0.20) Beats $(0.31) Estimate, Sales $52.40M Beat $42.68M Estimate

AAMI

ACCO

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CARR

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

ECVT

ELME

Earnings Scheduled For May 1, 2025

On Wednesday, Cathie Wood-led Ark Invest increased its exposure to NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>). These trades come amid ongoing challenges in the semiconductor industry, particularly with U.S. sanctions affecting chip sales to China.
The Nvidia Trade saw Ark Invest&#8217;s ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) acquiring 4,731 shares of NVIDIA. The stock closed at $102.71, marking a 3.86% increase from the previous day. The total value of this trade amounted to approximately $485,921.This purchase reflects Ark&#8217;s confidence in NVIDIA&#8217;s potential, even as Chinese tech giants like Alibaba and Tencent <a href="https://www.benzinga.com/25/04/44963176/chinese-tech-firms-led-by-alibaba-hoard-nvidia-ai-chips-amid-us-sanctions">stockpile NVIDIA&#8217;s AI chips</a> due to U.S. sanctions. These chips, specifically the H20 models, were designed to meet U.S. regulatory requirements, yet the looming threat of shipment restrictions has led to a surge in demand from Chinese companies.
The AMD Trade involved Ark&#8217;s ARKQ ETF purchasing 1,808 shares of Advanced Micro Devices. AMD&#8217;s stock saw a 4.79% rise, closing at $90.39. This acquisition, valued at around $163,425, comes as Ark continues to bolster its position in the semiconductor sector. On Tuesday, Ark had <a href="https://www.benzinga.com/25/04/44940763/ark-invests-bold-moves-nvidia-amd-airbnb-and-microsoft-in-focus">scooped up AMD shares</a> worth $2.14 million while picking Nvidia stock worth $1.09 million. Both these companies face U.S. export restrictions targeting China.
Other Key Trades:
<ul>
<li>Sold 182 Microsoft (MSFT) shares through ARKW</li>
<li>Sold 40,015 shares of UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from ARKF ETF and 8,273 shares through ARKW.</li>
<li>Bought 104,048 shares of Nurix Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) through ARKG.</li>
<li>Sold 147,820 shares of Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) in ARKG ETF.</li>
<li>Purchased 80,661 shares of 10X Genomics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) via ARKG ETF.</li>
</ul>
Benzinga Edge Stock Rankings show AMD has a Momentum in the 12th percentile and Growth in the 66th percentile. Wondering how Nvidia is placed? <a href="https://www.benzinga.com/25/04/44940763/ark-invests-bold-moves-nvidia-amd-airbnb-and-microsoft-in-focus">Click here</a> for the full picture.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/25/04/44940763/ark-invests-bold-moves-nvidia-amd-airbnb-and-microsoft-in-focus"><img loading="lazy" decoding="async" width="792" height="107" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23211526/Screenshot-2025-04-24-at-10.15.09.png" alt="" class="wp-image-885449" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23211526/Screenshot-2025-04-24-at-10.15.09.png 792w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23211526/Screenshot-2025-04-24-at-10.15.09-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23211526/Screenshot-2025-04-24-at-10.15.09-768x104.png 768w" sizes="(max-width: 792px) 100vw, 792px" /></a></figure>
Photo Courtesy: T. Schneider on Shutterstock.com
Read Next: <a href="https://benzinga.com/25/04/44942774/elon-musk-slams-tesla-protesters-says-they-benefited-from-government-waste-and-fraud-he-believes-to-have-cut-via-" target="_blank" rel="noreferrer noopener">​</a>
<ul>
<li><a href="https://benzinga.com/25/04/44942774/elon-musk-slams-tesla-protesters-says-they-benefited-from-government-waste-and-fraud-he-believes-to-have-cut-via-" target="_blank" rel="noreferrer noopener">Elon Musk Hits Out At Tesla Protesters, Says They Profited From Government &#8216;Waste And Fraud&#8217; He Cut Using DOGE: &#8216;They&#8217;re The Recipients Of Wasteful Largesse​&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

NRIX

NVDA

PATH

Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs

Shares of Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results and issued strong <a href="https://in.benzinga.com/news/buybacks/25/04/44911715/calix-stock-jumps-on-strong-q1-earnings-100-million-buyback-increase">second-quarter guidance</a>.
After market close on Monday, cloud and managed services company Calix announced that its board increased its buyback authorization by an additional $100 million, bringing the total repurchase authorization up to $162.9 million.
Calix reported first-quarter revenue of $220.24 million, beating analyst estimates of $206.98 million. The company reported first-quarter adjusted earnings of 19 cents per share, beating estimates of 13 cents per share, according to Benzinga Pro.
Calix shares jumped 13.1% to $37.61 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Gelteq Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) rose 329% to $3.97 in pre-market trading.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) surged 44.2% to $2.02 in pre-market trading. Smackover Lithium&#8217;s South West Arkansas Project has received a special designation as a priority transparency critical mineral project from the Trump Administration.</li>
<li>SUNation Energy Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) gained 36.2% to $3.80 in pre-market after dipping 30% on Monday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) surged 25.3% to $1.09 in pre-market trading after dipping over 22% on Monday.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) gained 25% to $15.25 in pre-market trading after falling around 20% on Monday.</li>
<li>IT Tech Packaging, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) jumped 22.4% to $0.2880 in pre-market trading after dipping 11% on Monday.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) rose 21.8% to $1.51 in pre-market trading r after the company announced it regained Nasdaq compliance.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) rose 17.4% to $3.98 in pre-market trading.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) gained 17% to $7.99 in pre-market trading. Adaptive Biotechnologies will report financial results for the first quarter after market close on Thursday, May 1.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>MKDWELL Tech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) fell 43.5% to $0.22 in pre-market trading after jumping over 70% on Monday.</li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) fell 36.7% to $0.1857 in pre-market trading after declining 5% on Monday.</li>
<li>SHF Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) shares fell 22.2% to $3.26 in pre-market trading after jumping around 96% on Monday.</li>
<li>Outset Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) shares tumbled 16.8% to $8.30 in pre-market trading. Outset Medical will release financial results for the first quarter after the close of trading on Wednesday, May 7.</li>
<li>National Energy Services Reunited Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) shares fell 16.4% to $5.00 in pre-market trading.</li>
<li>INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) fell 16.1% to $6.11 in pre-market trading.</li>
<li>Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) shares dipped 11.7% to $0.6890 in pre-market trading after dipping over 17% on Monday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) declined 9.3% to $10.65 in pre-market trading. USA Rare Earth will release financial results for the first quarter, after the closing bell on Wednesday, May 14.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 7.3% to $8.40 in today's pre-market trading.</li>
<li>SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) dipped 5.7% to $11.01 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

CALX

GELS

GURE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INMB

MKDW

NESR

SHF Holdings, Inc. - Class A Common Stock

SHFS

SITC

SUNE

TNMG

TYRA

USAR

Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares increased by 72.0% to $3.32 during Wednesday's pre-market session. The company's market cap stands at $87.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock increased by 17.82% to $3.9. The market value of their outstanding shares is at $59.3 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock rose 12.39% to $0.42. The market value of their outstanding shares is at $66.6 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) shares increased by 10.09% to $10.8. The market value of their outstanding shares is at $81.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares moved upwards by 9.06% to $0.98. The company's market cap stands at $16.2 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock rose 8.81% to $1.85. The company's market cap stands at $25.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) stock declined by 61.1% to $0.81 during Wednesday's pre-market session. The company's market cap stands at $25.2 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 15.13% to $1.74. The company's market cap stands at $7.9 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock decreased by 14.56% to $0.17. The market value of their outstanding shares is at $2.0 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) stock fell 13.44% to $6.7. The company's market cap stands at $988.7 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) stock decreased by 11.18% to $0.45. The market value of their outstanding shares is at $38.2 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares declined by 11.03% to $0.96. The market value of their outstanding shares is at $6.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASMB

BCDA

FORA

ICAD

IPSC

MIRA

RENB

SXTC

SYRA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Adaptive Biotechnologies shares are trading higher after the company announced that Palmetto GBA expanded its coverage of cloneSEQ.

Press Releases

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

General

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

Comments

Adaptive Biotechnologies

Noticias

Últimas noticias sobre Adaptive Biotechnologies (NASDAQ:ADPT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL